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Ropinirole Monotherapy
Induced Severe Reversible
Dyskinesias in Parkinson’s
Disease
Severe troublesome dyskinesias from dopamine agonist
(DA) monotherapy are very rare in humans. Of course, dyski-
nesias have been described, but generally these are not severe.1
However, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) primate models of Parkinson’s disease (PD), severe
dyskinesias from DA monotherapy may occur if the animals
are primed with levodopa.2 We describe here an unusual case
of a patient with early PD who developed severe dyskinesia on
ropinirole monotherapy that resolved completely on reducing
the dose. She had received levodopa previously, which was
stopped much earlier. We demonstrate, on serial videos, the
reversibility of the dyskinesias with dose reduction.
A 46-year old woman of Asian-Indian origin presented
with a 3-month history of left leg resting tremor. She had
left hemiparkinsonism and bilaterally reduced striatonigral
FIG. 1. Tremography shows bilateral tremor of the vastus medialis, with greater amplitude on the left side. Power spectrum analysis shows a domi-
nant frequency of 8–9 Hz. Coherence analysis also shows a significant peak at tremor frequency.
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uptake on dopamine transporter imaging, worse on the
right. There was no family history of PD, and she was nega-
tive for Parkin, LRRK2, G2019S, and synuclein multiplica-
tion. Routine blood tests and magnetic resonance imaging of
brain and cervical spine were normal. She was diagnosed
with PD (Hoehn & Yahr II) and started on levodopa (150
mg/day). She developed dyskinesias of the left foot within a
month after starting treatment, suggesting that this patient
was prone to develop early dyskinesias under dopaminergic
treatment. Levodopa was therefore gradually stopped, and
ropinirole was started and increased slowly initially to 9 mg/
day and then over 6 months to 15 mg/day. Within a month
of reaching this dose, she developed severe choreiform dyski-
nesias of the trunk, pelvis, fingers, hands, and feet (8 of 14
on Unified Parkinson’s disease Rating Scale-IV [UPDRS-IV]).
In fact, the choreiform movements were so pronounced that
a possibility of Huntington’s disease (HD) or similar disor-
ders was considered. Genetic tests for HD and dentato-
rubro-pallido-luysian atrophy were negative.
Ropinirole was reduced to 12 mg/day and dyskinesias
improved (UPDRS-IV 5 5; Video Segment 1) and then
reduced to 6 mg/day and dyskinesias completely disap-
peared. However, signs of parkinsonism reemerged (Video
Segment 2), and she was again treated with ropinirole,
reaching a dose of 9 mg/day, which benefited her but again
resulted in some mild dyskinesias (Video Segment 3).
Levodopa-induced dyskinesias are common and seen in
around 50% of PD patients at 5 years.3 These are usually at
higher doses, as evidenced in the Elldopa study.4 Dyskinesias
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developed in equal numbers of patients at 9 months (3.3%)
in the 150 mg/day and placebo groups; however, they were
significantly higher (16.5%) in 600 mg/day group. In con-
trast, dyskinesias with DA monotherapy are uncommon
(5%–7%), are milder in severity,5 and appear much later
(mean, 8.6 years of treatment with or without levodopa)
than levodopa-induced-dyskinesias.6 Initial priming with lev-
odopa may have contributed to the marked dyskinesias in
this patient, similar to that seen in animal models of PD.7
Reversibility has been described with dopamine agonist–
induced axial dystonia,8 but this has not been reported yet
with dyskinesia.
Indeed, MPTP-treated marmosets, briefly primed with lev-
odopa several months prior to DA introduction, developed
dose-dependent dyskinesias with ropinirole. These were simi-
lar in type and severity to those induced by levodopa.2 In
contrast, in nonprimed animals, dyskinesias were seen in
only 50%, were mild, and occurred at higher doses.2 Upreg-
ulated opiate transmission has been seen in 6-
hydroxydopamine-lesioned rat models of levodopa-induced-
dyskinesia and may be one of the possible pathways for dys-
kinesia accentuated with levodopa priming.9
Although marked dyskinesias are recognized in animal
models, our case is unique as these have not been described
in human patients on DA monotherapy. This case highlights
that similar to animal models, some PD patients may
develop marked dyskinesias with DA monotherapy when
primed earlier with levodopa, even with a small dose for a
short duration. It is possible that this particular patient may
have developed dyskinesias on DA monotherapy even with-
out levodopa priming, but this is speculative. Which PD
patients are vulnerable to such DA-induced, levodopa-
primed dyskinesias remains unanswered and may be estab-
lished by larger cohort studies.
Legend to the Video
Video Segment 1 (on 12 mg/day ropinirole). Moderate
trunk and pelvic dyskinesias with choreiform dyskinesias in
the hands and legs.
Video Segment 2 (on 6 mg/day ropinirole). Severe tremor
and marked bradykinesia on the left side without
dyskinesias.
Video Segment 3 (on 9 mg/day ropinirole). Mild dyskine-
sias and mild parkinsonian features with asymmetric
bradykinesia.
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“Occam’s Razor” and Identical
Twins With Discordant
Parkinson’s Disease
Entia non sunt multiplicanda praeter necessitatem (it is
vain to do with many what can be done with few).
For many clinicians, it may be difficult to fully appreci-
ate the practical and pathological significance of the tsu-
nami of reported advances in genomics, obtained at
“visceral” expense.1 It is salutary and refreshing to read a
brief, illuminating, and potentially very significant short
report2 in which Xiromerisiou et al describe identical
twins with leucine-rich repeat kinase type 2 mutations
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